David Attwood
Director of Finance/CFO chez THCinol/CBDinol CanPharma GmbH
Profil
David Attwood is currently the Chief Financial Officer at THCinol.
Prior to this, he was the Chief Executive Officer at Health House International Ltd.
from 2021 to 2023.
Mr. Attwood is a graduate of The University of Nottingham and holds an MBA from Instituto de Estudios Superiores de la Empresa.
Postes actifs de David Attwood
| Sociétés | Poste | Début |
|---|---|---|
THCinol/CBDinol CanPharma GmbH
 THCinol/CBDinol CanPharma GmbH Pharmaceuticals: OtherHealth Technology Part of CanPharma GmbH /Jacker/, THCinol/CBDinol CanPharma GmbH is a German company that brings years of experience in the treatment with cannabinoids and necessary expertise to ensure a professional handling of medical cannabis. The private company is based in Oranienburg, Germany. The company aims to fully unleash the potential of medical cannabis with a focus on the well-being of the patient. The company offers quality products, specialized information, and a CanPharma patient ID. The company was founded by Holger Sprengel and Henrik Arne Sprengel, with Henrik Arne Sprengel serving as CEO since incorporation. THCinol/CBDinol CanPharma was acquired by CanPharma GmbH /Jacker/ from Health House International Ltd. on November 16, 2022. | Director of Finance/CFO | - |
Anciens postes connus de David Attwood
| Sociétés | Poste | Fin |
|---|---|---|
| HEALTH HOUSE INTERNATIONAL | Chief Executive Officer | 19/03/2023 |
Formation de David Attwood
| The University of Nottingham | Graduate Degree |
| Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Health House International Ltd.
 Health House International Ltd. Pharmaceuticals: OtherHealth Technology Health House International Ltd. engages in the distribution of medicinal cannabis. The company was founded by Jason Peterson and Harry Karelis in 2014 and is headquartered in Melbourne, Australia. | Health Technology |
THCinol/CBDinol CanPharma GmbH
THCinol/CBDinol CanPharma GmbH Pharmaceuticals: OtherHealth Technology Part of CanPharma GmbH /Jacker/, THCinol/CBDinol CanPharma GmbH is a German company that brings years of experience in the treatment with cannabinoids and necessary expertise to ensure a professional handling of medical cannabis. The private company is based in Oranienburg, Germany. The company aims to fully unleash the potential of medical cannabis with a focus on the well-being of the patient. The company offers quality products, specialized information, and a CanPharma patient ID. The company was founded by Holger Sprengel and Henrik Arne Sprengel, with Henrik Arne Sprengel serving as CEO since incorporation. THCinol/CBDinol CanPharma was acquired by CanPharma GmbH /Jacker/ from Health House International Ltd. on November 16, 2022. | Health Technology |
